TFS Capital’s Biolase, Inc. BIOL Stock Holding History

TFS Capital’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-3	Closed	-$76K	–	1674
2013 Q3	$76K	Buy	+3	New	+$96.6K	﹤0.01%	1374

Other funds holding BIOL

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PCMI

Princeton Capital Management Inc Princeton, New Jersey $198M AUM 28.98% 1-Year Est. Return

Teton Advisors Rye, New York $142M AUM 42.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TFS Capital's BIOL Position: Q4 2013 in Review

TFS Capital sold out of Biolase, Inc. (BIOL) in Q4 2013, closing a stake of 3 shares — an estimated $76K sold.

TFS Capital first reported a position in BIOL in Q3 2013 and held it in 1 quarter. The position peaked at $76K in Q3 2013. 39 funds tracked by Wall St. Rank hold BIOL as of Q4 2013.

TFS Capital reported no remaining Biolase, Inc. position as of Q4 2013 after selling out during the quarter.
TFS Capital sold 3 Biolase, Inc. shares in Q4 2013, an estimated $76K.
TFS Capital first reported a position in Biolase, Inc. in Q3 2013 and held it in 1 quarter.
TFS Capital's Biolase, Inc. position peaked at $76K in Q3 2013.
39 funds tracked by Wall St. Rank held Biolase, Inc. as of Q4 2013.

Based on TFS Capital's 13F filing for Q4 2013, filed 7 Feb 2014.